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Foot and Ankle Problems in Patients With Rheumatoid 
Arthritis in 2019: Still an Important Issue
Morten Bilde Simonsen,1  Kim Hørslev- Petersen,2  Maria C. Cöster,3  Carsten Jensen,4  and 
Ann Bremander5
Objective. To study the prevalence of foot pain in patients with rheumatoid arthritis (RA) and whether including a 
12- joint foot count in addition to the 28- joint count (from the Disease Activity Score 28 [DAS28]) improved detection 
of foot or ankle pain. In addition, the association between the self- reported foot and ankle score (SEFAS), patient- 
reported function, and disease- specific factors was studied.
Methods. Physician- reported data (swollen/tender 12- joint foot count, DAS28, and medication) and patient- 
reported data (foot/ankle pain, physical function, global health, and SEFAS) were assessed during a clinical visit. 
Data were analyzed with t test, χ2 tests, and regression analysis.
Results. A total of 320 patients with RA were included (mean age 63 years, SD 13 years; 73% women), of whom 
69% reported foot or ankle pain. Patients who reported foot or ankle pain had a lower mean age and worse disease 
activity, general pain, function, and global health (P ≤ 0.016), and fewer were in remission (50% versus 75%; P < 
0.001) compared with patients without foot pain. The 12- joint foot count identified 3.2% and 9.5% additional patients 
with swollen and tender joints, respectively, compared with the 28- joint count. The SEFAS was associated with 
walking problems (β = −2.733; 95% confidence interval [CI] = −3.963 to −1.503) and worse function (β = −3.634; 95% 
CI = −5.681 to −1.587) but not with joint inflammation severity.
Conclusion. The prevalence of foot or ankle pain in patients with RA is high. The 12- joint foot count had minor 
effects on detecting patients with foot pain. However, the SEFAS contributed additional information on foot problems 
that was not identified by joint examinations alone.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, systemic inflamma-
tory disease, and its prevalence in the Nordic adult population 
is approximately 0.9% (1). The feet and ankles are commonly 
affected by the disease, and synovitis may lead to tenderness, 
swelling, pain, stiffness, joint destruction, and altered foot mechan-
ics, which increase the risk of falls and impair quality of life (2– 5). 
New and more effective medication and the treat- to- target strat-
egy have placed more patients in remission and decreased the 
number of patients in need of surgical treatment (6,7). Neverthe-
less, 70% to 90% of the RA population still report daily pain from 
the feet or ankles (8,9). As many as one- third of the patients in 
remission may present with foot synovitis, which increases the 
risk of structural joint damage (3). These problems are sometimes 
underestimated and undertreated by the physician because the 
foot joints are not part of the composite global disease activ-
ity indice, the 28- joint evaluation (the Disease Activity Score 28 
[DAS28]). The DAS28, recommended by the American College 
of Rheumatology and the European League Against Rheuma-
tism (EULAR) as a measure of disease activity in patients with 
RA, is used daily in clinical practice to define clinical remission 
and guide medical treatment (10,11). In the mid- 1990s, a disease 
activity score including an evaluation of 44 joints was modified into 
the DAS28, and swollen and tender joints in the feet and ankles 
were omitted (12). Even though the DAS28 is considered to reflect 
overall joint inflammation (12), some clinics still assess swollen and 
painful metatarsophalangeal joints and ankles (13). Foot or ankle 
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problems could potentially be an issue in the early stages of RA 
as well as later, in more advanced stages, when deformities may 
occur (12,13), which is why relying only on the DAS28 to identify 
foot pain may delay treatment and increase the risk for joint dam-
age in the feet.
In addition, the DAS28 or the 12- joint count do not assess 
other issues commonly found in people with RA (14), nor do they 
capture physical functioning and disability due to foot pain. For 
this reason, a supplementary patient- reported outcome measure 
(PROM) of foot and ankle problems is needed. The self- reported 
foot and ankle score (SEFAS) is a commonly used questionnaire 
for people with RA and foot problems (15). The SEFAS meas-
ures the constructs of pain and functional status. By including 
the SEFAS to reflect the patients’ view as a supplement to the 
rheumatologists’ joint assessment, the consequences of living 
with foot pain can be better understood and treated.
This study aimed to assess the prevalence of foot and ankle 
pain in patients with RA attending a specialist clinic and whether 
inclusion of the swollen and tender 12- joint foot count in addition 
to the 28- joint count in the DAS28 improved detection of foot or 
ankle pain. Furthermore, the association between SEFAS, patient- 
reported function, and disease- specific factors was studied.
PATIENTS AND METHODS
Recruitment. Participants were consecutively recruited 
from the Danish Hospital for Rheumatic Diseases from Septem-
ber 2019 to December 2019. Adults (≥18 years) with a diagnosis 
of RA (16) attending rheumatology care at the hospital who were 
capable of reading and understanding Danish were included.
Data collection. All participants were asked an initial ques-
tion “Do you experience any pain in your feet or ankles at this clin-
ical visit?” Patients who reported foot or ankle pain were asked to 
complete the SEFAS questionnaire and were asked the following 
two additional questions: “Did your foot or ankle problems start 
before or after you were diagnosed with RA?" and “Is it a unilateral 
or bilateral problem?” In addition, ordinary clinical parameters reg-
istered in the Danish nationwide database of patients with inflam-
matory arthritis (DANBIO) from the same visit were extracted (17).
Clinical data. The patients’ clinical data were used to 
describe differences between patients with versus without foot or 
ankle pain. Some parameters were physician recorded, includ-
ing diagnosis, age, disease duration, sex, medication, C- reactive 
protein (CRP), swollen and tender joints (28- joint count), swollen 
and tender metatarsophalangeal and ankle joint (pressure point 
between the extensor hallucis longus tendon and the exten-
sor digitorum longus tendon) count (12- joint foot count), and 
physician- rated global health. Some parameters were patient- 
reported, including global health, pain intensity, fatigue (all rated 
on a visual analog scale ranging from 0 to 100 [best to worst]), and 
function (Health Assessment Questionnaire [HAQ]).
Medication was divided into conventional synthetic disease- 
modifying antirheumatic drug (csDMARD) and biological disease- 
modifying antirheumatic drug (bDMARD) groups. If a patient 
received both a csDMARD and a bDMARD, they were included in 
the bDMARD group.
The composite score DAS28 ranges from 0.96 to 9.4 (best 
to worst) and consists of the number of swollen and tender joints 
(the 28- joint count),CRP, and the patient- reported global health 
scale (18). Remission was defined as a DAS28 CRP of less than 
2.6 and no swollen joints according to the 28- joint evaluation (19). 
The 28- joint evaluation includes joints in the hands (10 per hand), 
wrist, elbow, shoulder, and hips. The 12- joint foot count includes 
the ankle joint and the five metatarsophalangeal joints of both feet 
(20).
The HAQ measures function and consists of 20 questions, 
with a summary score ranging from 0 to 3 (best to worst) (21). The 
following two additional questions on physical function, recorded 
in the DANBIO, were also included: 1) Can you walk 3 km (if you 
want to)? and 2) Can you participate in sport and leisure activities 
(if you want to)? Both are scored on a Likert scale ranging from 0 
to 3 (0 = yes, without any problems; 3 = no, I cannot).
Self- reported foot or ankle problems. The SEFAS 
for patients with RA was originally developed for surgical inter-
ventions in the foot and ankle (15). The questionnaire assesses 
foot problems over the last 4 weeks, contains 12 items with five 
response options, and takes less than 5 minutes to complete. 
The questionnaire covers pain, functional limitations, and other 
symptoms. Each of the 12 multiple- choice questions is scored 
from 0 to 4, where a sum of 0 points represents the most severe 
disability and a score of 48 points represents normal function. 
The SEFAS scoring was handled according to the manual (15). 
The SEFAS is available in several languages and has been trans-
lated into Danish (22), and we adapted the Danish version to our 
group of patients (nonsurgical). To confirm methodological quality 
(23), we confirmed that the face and content validity, construct 
SIGNIFICANCE & INNOVATIONS
• Foot and ankle pain are common complaints among 
patients with rheumatoid arthirtis throughout 
the disease course, affecting their overall health. 
Therefore, improving detection and treatment of 
foot and ankle pain is important.
• Of patients who reported foot pain, 9 of 10 did not 
have any swollen foot joints, and 6 of 10 did not 
have any tender foot joints.
• Including a single question concerning foot pain as 
a screening tool in clinical practice or a more com-
prehensive patient- reported outcome measure 
such as the self- reported foot and ankle score can 
be recommended.
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validity (>78% of predefined hypothesis confirmed), internal con-
sistency (Cronbach’s α = 0.89), floor and ceiling effects (0.4% and 
0.9%), and test- retest (intraclass correlation coefficient = 0.97) of 
the SEFAS met the requirements (Supplementary Tables 1– 2, and 
Supplementary Figure 1).
Ethics. The study was conducted in accordance with the 
Declaration of Helsinki. All patients were informed orally and in 
writing, and informed written consent was obtained. The Eth-
ical Committee for Health Research of the Region of Southern 
Denmark approved the study (20192000- 98). The project was 
presented to the patient user council at the Danish Hospital 
for Rheumatic Diseases, which recommended the project and 
pointed out feet in RA as an important research area.
Statistics. All data were tested for normality using a Shapiro- 
Wilk test, and t- tests or χ2 tests were used to compare patients 
with foot or ankle pain with those without foot or ankle pain. The 
relationship between the 28- joint count and the 12- joint count was 
investigated with a contingency table. A linear regression analy-
sis was used to study factors associated with self- reported foot 
problems (with SEFAS as the dependent variable) and patient- 
reported function and disease- specific factors. Two models were 
used. The first model was a crude analysis with one independent 
variable at a time, controlled for age and sex. The second model 
contained all variables, including age and sex. Statistical analysis 
was performed in SPSS version 26 (https://www.ibm.com/produ 
cts/spss- stati stics).
RESULTS
Patients. In the present study, 333 patients responded to 
the survey. Three patients did not have an RA diagnosis and were 
excluded, and one patient was later found to have been included 
twice, which is why the second clinical visit was excluded from the 
analysis. A further eight patients were excluded because they did 
not have data registered in DANBIO corresponding to the clinical 
visit. One patient had moved from the area at the time of data 
extraction and had to be excluded. The 320 patients had a mean 
age of 63.7 (SD 12.9) years and a median disease age of 11.5 
years (ranging from 1 month to 55 years), and 72.8% of those 
included in the analysis were women.
Prevalence of foot or ankle pain. In the present study, 
69% (220/320) of the patients reported present foot or ankle pain. 
Among them, 71% had bilateral foot or ankle pain. A total of 70% 
of the patients with foot or ankle pain did not experience pain 
prior to being diagnosed with RA. Data comparing patients with 
and without foot or ankle pain are presented in Table 1. No dif-
ference was found in disease duration or CRP between the two 
groups. Patients who reported foot or ankle pain were younger 
and had worse reports in all other studied variables, indicating 
worse overall health compared with patients who did not report 
foot or ankle pain. A smaller proportion of patients with foot or 
ankle pain were in remission (48% versus 75%; P < 0.001), and a 
larger proportion received bDMARD or csDMARD treatment com-
pared with those without foot or ankle pain (P < 0.001), indicating 
a higher disease activity (Table 1).
Physician- reported swollen and tender foot joints. In 
the group reporting foot and ankle pain (n = 220), the 12- joint foot 
count identified seven additional patients (3.2 %) with one or more 
swollen joints and 21 patients (9.5 %) with one or more tender joints 
who were not captured with the 28- joint count (Tables 2 and 3). Con-
sequently, the combination of the 28- joint count and the 12- foot joint 
count did not record any swollen or tender joints for 78.2% and 41.8% 
of the patients reporting foot pain, respectively (Tables 2 and 3).
In the group of patients who reported no foot or ankle pain 
(n = 100), the physician- reported 12- joint foot count did not 
Table 1. Descriptive data
Characteristics
Foot Pain  
(n = 220)
No Foot Pain  
(n = 100) P Value
Sex, male, n (%) 47 (21) 40 (40) <0.001
csDMARD, n (%) 126 (57.2) 66 (66) <0.001
bDMARD, n (%) 94 (42.8) 38 (38) <0.001
Remission, n (%) 107 (48.9) 75 (75) <0.001
Age, yr 62.5 (12.9) 66.3 (12.4) 0.016
Disease duration, yr 13.4 (10.5) 12.1 (8.9) 0.222
CRP 6.3 (10.8) 5.2 (8.6) 0.502
HAQa 0.9 (0.7) 0.4 (0.5) <0.001
Global healthb 42.0 (28.2) 22.0 (24.2) <0.001
Painb 36.4 (25.6) 21.1 (24.4) <0.001
Fatigueb 47.5 (28.9) 26.6 (26.2) <0.001
Physician- reported 
global healthb
12.9 (15.3) 8.1 (10.0) <0.001
DAS28c 2.7 (1.2) 2.0 (0.9) <0.001
Swollen 28- joint count 0.8 (2.4) 0.2 (1.1) 0.015
Tender 28- joint count 2.5 (4.3) 0.9 (2.6) <0.001
Swollen 12- joint count 0.2 (1.1) 0.0 (0.0) 0.004
Tender 12- joint count 1.7 (1.7) 0.2 (1.4) <0.001
3- km walk 1.2 (1.1) 0.6 (1.0) <0.001
Sport and leisure 1.4 (1.1) 0.9 (1.0) 0.001
SEFASd 26.9 (9.3) - - 
CRP, C- reactive protein; DAS28, Disease Activity Score 28; HAQ, 
Health Assessment Questionnaire; SEFAS, self- reported foot and 
ankle score.
Values are given in mean (SD) unless otherwise indicated.
a Scored from 0 to 3 (best to worst). 
b Global health, pain, and fatigue visual analog scale is measured 
from 0 mm to 100 mm (best to worst). 
c The 28- joint disease activity score scored from 0.96 to 9.4 (best to 
worst). 
d Scored from 0 to 48 (worst to best). 
Table 2. Distribution of swollen joints in patients reporting foot pain 





0 swollen 28 joints, n (%) 172 (78.2) 7 (3.2)
≥1 swollen 28 joints, n (%) 31 (14.1) 10 (4.5)
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register any swollen joints, and tender joints were registered for 
three patients (3%).
Foot and ankle– specific PROM. The average SEFAS 
summary score for the group with foot or ankle pain was 26.95 
(SD 9.3). The multivariate model explained 77% of the variation 
(R2= 0.767), and variables concerning physical function were 
associated with the SEFAS, as follows: a worse HAQ (esti-
mated β = −3.634; 95% confidence interval [CI] = −5.681 to 
−1.587), problems with walking 3 km (estimated β = −2.733; 
95% CI = −3.963 to −1.503]), and problems with participating in 
sport and recreational activities (estimated β- est = −1.290; 95% 
CI = −2.438 to −0.142) indicated a worse (lower) SEFAS (Table 4). 
There was a negative borderline association with a higher num-
ber of physician- reported tender 12- joint foot counts (estimated 
β = −0.345; 95% CI = −0.707 to 0.017) and a worse SEFAS, 
whereas swollen 12- joint foot count, disease activity (DAS28), and 
disease duration were not associated with the SEFAS (Table 4).
DISCUSSION
A large proportion of patients with RA experience foot or 
ankle pain throughout the disease course, affecting their over-
all health. Therefore, monitoring the feet remains highly relevant. 
Omission of the feet from the disease activity score has received 
criticism; it limits the clinicians’ focus on the feet (3,13). The 
present study found that the 12- joint foot count identified 9.5% 
of patients with tender joints and 3.2% with swollen joints, which 
was not captured with the 28- joint count alone. However, 92.3% 
and 61.4% of the patients reporting foot pain did not have any 
swollen or tender joints in the examined foot joints, respectively. 
Furthermore, no swollen foot joints were observed among the 
patients without foot pain, and only three patients from this group 
had tender joints. The high prevalence of pain reported may have 
been due to hindfoot, midfoot, or other soft tissue diseases that 
were not measured in the current study. Therefore, joint exam-
ination should not stand alone. Asking the patients about pain 
in their feet or ankles or including a PROM will provide additional 
information on foot problems not identified by joint examinations. 
The SEFAS used in this study indicates a somewhat high level of 
foot problems, and the score was associated with other physical 
functioning measures.
One of the study’s aims was to investigate the prevalence of 
foot or ankle pain among patients with RA. Seven of 10 patients 
reported that they currently had pain in their feet, most often bilat-
eral. The prevalence found in the present study is in the lower 
range compared with previous studies investigating the preva-
lence of current foot and ankle problems among patients with RA. 
An interval within 68% to 94% was reported from studies per-
formed from 1956 to 2017 (8,9,24– 29). This could indicate that 
the current management of the disease has slightly reduced the 
prevalence of foot or ankle pain in patients with RA compared with 
the previous investigations on foot and ankle problems. However, 
this finding must be interpreted with caution; the prevalence is 
still high. It is also important to note that some previous studies 
investigated the prevalence of foot problems (8,24– 29), whereas 
the present study investigated the prevalence of foot and ankle 
pain. The higher prevalence reported in previous studies could be 
due to “foot problems” covering numerous types of problems (eg, 
Table 3. Distribution of tender joints in patients reporting foot pain 
(n = 220) identified by the 28- joint count and 12- joint count
0 tender foot 
joints
≥ 1 tender 
foot joints
0 tender 28 joints, n (%) 92 (41.8) 21 (9.5)
≥1 tender 28 joints, n (%) 43 (19.5) 64 (29.1)
Table 4. Linear regression analysis with SEFAS (0- 48; worst to best) as the dependent variable
Model 1 Model 2
R Value β- est 95% CI P Value β- est 95% CI P Value
Sex (male =1, female= 0) - - - - −0.950 −3.224 to 1.325 0.411
Age, yr - - - - 0.031 −0.045 to 0.107 0.442
Disease duration, yr 0.22 0.000003 −0.01 to 0.01 1 0.0002 −0.008 to 0.008 0.943
HAQa 0.68 −9.052 −10.431 to −7.673 <0.001 −3.634 −5.681 to −1.587 0.002
Physician- reported global 
healthb
0.46 −0.276 −0.356 to −0.195 <0.001 −0.066 −0.164 to 0.031 0.18
DAS28c 0.54 −3.958 −4.842 to −3.074 <0.001 −0.515 −1.733 to 0.702 0.405
Swollen 12- joint count 0.29 −1.543 −2.642 to −0.445 0.006 0.685 −0.335 to 1.675 0.174
Tender 12- joint count 0.40 −1.037 −1.413 to −0.661 <0.001 −0.345 −0.707 to 0.017 0.061
3- km walk 0.67 −5.691 −6.612 to −4.771 <0.001 −2.733 −3.963 to − 1.503 <0.001
Sport and recreational activities 0.60 −4.855 −5.794 to −3.916 <0.001 −1.290 −2.438 to −0.142 0.028
β- est, estimated β; CI, confidence interval; HAQ, Health Assessment Questionnaire; DAS28, Disease Activity Score 28; SEFAS, self- reported foot 
and ankle score.
Model 1 = one independent variable at a time controlled for age and sex. Model 2 = all variables included; age and sex are entered into the same 
model.
a Scored from 0 to 3 (best to worst). 
b Global health, pain, and fatigue visual analog scale is measured from 0 mm to 100 mm (best to worst). 
c The 28- joint disease activity score scored from 0.96 to 9.4 (best to worst). 
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cosmetics, deformities, and issues with finding footwear; some of 
these can be pain- free problems). In contrast, foot and ankle pain 
is related to the sensation of pain in the feet or ankles. The present 
study results also found that patients reporting current foot and 
ankle pain had worse records in all studied variables except dis-
ease duration and CRP, indicating worse overall health compared 
with the patients without foot and ankle pain. Therefore, attention 
should be paid to patients’ feet, whether they are in remission or 
not.
In the present study, 70% of the patients with foot or ankle 
pain did not have pain in the region before being diagnosed with 
RA, indicating that the joint complaint is disease related. Disease 
duration in RA has previously been considered an important factor 
for persistent foot or ankle pain (30). A longer disease duration may 
have impacted residual pain in the absence of disease activity. 
Patients with longer disease duration often have more pain and 
less disease activity than those in earlier disease stages (30). No 
difference in disease duration was observed between the patients 
with foot pain and those without foot pain. This finding highlights 
the importance of including the feet in the clinical assessment 
from the start and throughout the course of the disease.
The DAS28 score is often criticized for not including the feet 
and ankles to determine disease activity (3,8,31). The present 
study found that the 12- joint foot count would slightly improve 
pain detection in the feet and ankles. Adding the 12- joint foot 
count alone will not be sufficient, as some patients may still risk 
having their foot problems overlooked by health care profession-
als. A probable explanation for the joint assessments’ limited 
detection ability could be that foot and ankle pain in patients with 
RA does not necessarily originate from the examined joints; it 
could be present in other structures, (eg, tendons and muscles) 
(27,32). The assessment of foot problems and foot biomechanics 
is a key issue in unmet needs that requires research by the EULAR 
research roadmap (33). Previous studies have also suggested a 
need for a tool to monitor the feet in patients with RA (8,34,35).
An additional improvement to the clinical assessment of 
joint examination could be to include patient- reported measures 
regarding the feet at outpatient consultations. As a start, a sim-
ple yes/no question might facilitate a discussion concerning foot 
problems between patient and physician. If added information 
is needed, the SEFAS or a similar self- reported measure of foot 
problems can be used, such as the recently introduced Rheuma-
toid Foot Disease Activity Index- 5 (34).
The SEFAS was developed to evaluate pain, functional limi-
tations, and other symptoms. The present study results show that 
the SEFAS is associated with daily activities in patients with RA 
who have foot and ankle pain, indicating that the SEFAS may be 
a useful tool to evaluate foot and ankle problems in patients with 
RA. The mean summary score in the present study was worse 
than the normative values found in a population- based sample 
(36). The summary score from the present study was similar to 
that of patients admitted to surgery for hallux valgus deformity (37) 
and forefoot disorders (38) but better than presurgical scores in 
patients with ankle or hindfoot disorders (38). Results based on 
the SEFAS in the present study indicate that patients with RA and 
foot or ankle pain experience functional limitations comparable 
with those of some individuals planned for foot surgery. However, 
the SEFAS’ discriminative validity needs to be further studied.
The consecutive enrollment of patients in this study might 
challenge the external validity. Because the patients were recruited 
during the fall, the seasonal impact on flares was not accounted 
for. Earlier studies suggest a seasonal variation in disease activ-
ity, with higher disease activity scores during winter and spring 
but lower in the fall (39,40). If the data had been collected 2 to 
3 months later, the prevalence of foot and ankle pain might have 
been higher. Another limitation relates to only asking about current 
level foot/ankle pain rather than the past week. We only asked 
about current pain to make a direct comparison to the clinical 
assessment. This decision may have affected the number of 
included subjects, and we might have included more patients with 
foot pain if we had asked about pain during longer time frame (eg, 
past week). The SEFAS was, in the present study, used in an RA 
population attending regular clinical visits, which is slightly different 
from the surgical focus where the SEFAS was initially developed 
and tested for methodological quality. The studied methodolog-
ical properties based on this population were good. However, 
the questionnaire needs to be further validated in this nonsurgi-
cal population. Body mass index (BMI) was not recorded in the 
present study. Therefore, it has not been possible to include BMI 
in the regression models. Also, the 12- joint count is limited by lack 
of details; it is possible that adding the hindfoot and soft tissues 
(eg, ankle tendons) to the examination would improve monitoring 
of the feet. Future studies need to examine this. Finally, medical 
imaging (eg, X- ray, magnetic resonance imaging, and ultrasound) 
was not included in the present study. Medical imaging could have 
been used to examine whether there were structural changes in 
the feet and ankles (34,41).
A strength of the study is, firstly, that patients were recruited 
from a hospital specialized in the target- to- treat approach and 
who routinely perform the 12- joint foot count, thus strengthening 
the validity and reliability of the test. Secondly, the patients’ disease 
duration was widely represented, ranging from newly diagnosed 
patients to patients with more than 15 years of disease duration. 
Therefore, we consider the included patients as representative for 
a specialist clinic.
The present study found that 7 of every 10 patients with RA 
reported foot and ankle pain and that foot and ankle pain was 
common throughout the disease course. These results indicate 
that many patients in remission experience foot and ankle pain in 
RA. Therefore, monitoring the feet in patients with RA is still essen-
tial. However, the presence of pain does not necessarily mean 
poor inflammatory control, as residual pain often persists because 
of joint damage and may also be part of a more widespread pain 
problem (42). Including the assessment of swollen and tender 
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ankle and metatarsophalangeal joints does not identify all patients 
with foot pain. Therefore, the 12- joint foot count of the foot and 
ankle should not be the only assessment of the feet. Including a 
single question concerning the presence of foot pain or a PROM, 
such as the SEFAS or similar, will contribute with additional infor-
mation on foot problems not identified by joint examinations 
and may facilitate a patient– physician discussion.
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